In Part 1 of this series, general wellness devices and mobile medical applications (MMAs) will be considered. Part 2 of this series will be devoted to clinical decision support (C
Digital health tools hold huge potential, and the evidence base is growing all the time – so what is holding us back and how does the sector overcome the multiple barriers to widespread ado
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh